|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Resminostat>> Market Analysis Reports |
Market Analysis Reports of Resminostat |
|
4 SC AG Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC ... Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018 Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018 SUMMARY Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 ... Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drugs in Development, 2021 Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drugs in Development, 2021 SUMMARY Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 ... Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the recently published report 'Histone Deacetylase 4 - ... Sezary Syndrome - Pipeline Insghts, 2022 ... being developed by Innate Pharma. Resminostat: 4SC Resminostat is an orally administered histone ... cancer drugs. In preclinical models, resminostat has shown selectivity for ... HDAC6, which is active in metastasis. Resminostat has the potential to provide ... Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H2 2018 Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H2 2018 SUMMARY Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 ... Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H1 2018 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H1 2018 SUMMARY According to the recently published report 'Histone Deacetylase 2 - Pipeline Review, H1 2018'; Histone ... Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018 Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018 SUMMARY Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase ... Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the recently published report 'Histone Deacetylase 1 - Drugs In ... Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Histone ... Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are ... Cutaneous T- Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2028 This report can be delivered to the clients within 24 Hours DelveInsight’s ‘Cutaneous T- Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted ... Mycosis Fungoides (MF) - Market Insights, Epidemiology and Market Forecast-2028 This report can be delivered to the clients within 24 Hours DelveInsight’s ‘Mycosis Fungoides (MF) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as ... Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017 This report can be delivered to the clients within 25 Hours DelveInsight’s, “Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market, and Pipeline Analysis, 2017” report provides comprehensive insights of the ongoing therapeutic research and ... Histone Deacetylase 4 - Pipeline Review, H2 2020 Histone Deacetylase 4 - Pipeline Review, H2 2020 SUMMARY Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine ... Hodgkin’s Lymphoma – Pipeline Insight, 2021 ... Products AFM 13 Camidanlumab tesirine Sugemalimab Resminostat TGR-1202 T cell lymphoma - Pipeline Insight, 2021 ... SP-02L SP-02 Sintilimab SHC014748M SGN-35 RP6530 Resminostat Pembrolizumab PBCAR20 Nivolumab MLN 9708 ... Cutaneous T-Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major cutaneous T-cell lymphoma markets reached a value of US$ 428.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 628.7 Million by 2034, exhibiting a growth rate (CAGR) of 3.55% during 2024-2034. The cutaneous T-cell ... Mycosis Fungoides Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major mycosis fungoides markets are expected to exhibit a CAGR of 4.9% during 2024-2034. The mycosis fungoides market has been comprehensively analyzed in IMARC's new report titled "Mycosis Fungoides Market: Epidemiology, Industry Trends, Share, Size ... Sezary Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major Sezary syndrome markets are expected to exhibit a CAGR of 3.99% during 2024-2034. The Sezary syndrome market has been comprehensively analyzed in IMARC's new report titled "Sezary Syndrome Market: Epidemiology, Industry Trends, Share, Size, ... |